Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus XELOX versus XELOX alone in second-line metastatic colorectal cancer
2007-004866-42Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab, capecitabine and oxaliplatin in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Progression-free survival rate at 6 months. Started Mar 2009; status: terminated.
02
Drugs
panitumumabcapecitabineoxaliplatin
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2007-004866-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004866-42.